H.C. Wainwright & Co.

In a report published Friday, H.C. Wainwright & Co. analyst Reni Benjamin reiterated a Buy rating and $15.00 price target on Spectrum Pharmaceuticals (NASDAQ: SPPI). In the report, H.C. Wainwright & Co. noted, “We are reiterating our BUY rating for Spectrum Pharmaceuticals and a 12-month...

In a report published Friday, H.C. Wainwright & Co. analyst Reni Benjamin reiterated a Buy rating and $19.00 price target on Keryx Biopharmaceuticals (NASDAQ: KERX). In the report, H.C. Wainwright & Co. noted, “We are reiterating our BUY rating on Keryx Pharmaceuticals and maintaining our...

Vertex Pharmaceuticals (NASDAQ: VRTX) reported earnings after the bell on Tuesday, July 29, that beat consensus estimates. Despite the beat, the stock declined in Wednesday's trading action by 3.73 percent. Credit Suisse reiterated a Neutral rating, $94 price target: “VRTX reported non-GAAP EPS...

In a report released Thursday, H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage on AEterna Zentaris (NASDAQ: AEZS) with a Buy rating and a 12-month price target of $3.00 per share. Analysts at H.C. Wainwright favor AEterna for the likelihood of its drug Macrilen passing its FDA...

In a note released Tuesday morning, H.C. Wainwright analyst Andrew Fein initiated a Buy on both Epizyme (NASDAQ: EPZM) and Transition Therapeutics (NASDAQ: TTHI) and set respective price targets of $40 and $10. Epizyme Amid the transition of big pharma from genetics to epigenetics, Fein likes...

In a report published Tuesday, H.C. Wainwright & Co. analyst George B. Zavoico initiated coverage on OXiGENE (NASDAQ: OXGN) with a Buy rating and $7.50 price target. In the report, H.C. Wainwright & Co. noted, “We are initiating coverage of OXiGENE with a BUY recommendation and a $7.50 one...

In a report published Monday, H.C. Wainwright & Co. analyst Amit Dayal initiated coverage on MeetMe (NYSE: MEET) with a Buy/ Speculative Risk rating and $5.00 price target. Dayal noted that MeetMe's audience continued to engage with the platform via mobile. The analyst remarked that this is...

In a report published Monday, H.C. Wainwright & Co. analyst Andrew Fein initiated coverage on PharmAthene (NYSE: PIP) with a Buy rating and $4.00 price target. Fein noted that shares represent an attractive point with “transformative” events over the next six months. The analyst wrote that the...

In a report published Monday, H.C. Wainwright & Co. analyst Andrew S. Fein initiated coverage on Seattle Genetics (NASDAQ: SGEN) with a Buy rating and $65.00 price target. In the report, H.C. Wainwright & Co. noted, “We believe that Adcetris, anti-CD30-targeted antibody drug conjugate (ADC...

In a report published Monday, H.C. Wainwright & Co. analyst Andrew S. Fein initiated coverage on BioCryst Pharmaceuticals (NASDAQ: BCRX) with a Buy rating and $21.00 price target. In the report, H.C. Wainwright & Co. noted, “Biocryst's BCX4161 (a potent oral kallikrein inhibitor) recently...

In a report published Monday, H.C. Wainwright & Co. analyst Reni Benjamin initiated coverage on GenVec (NASDAQ: GNVC) with a Buy rating and $9.00 price target. In the report, H.C. Wainwright & Co. noted, “We are initiating coverage of GenVec with a BUY rating and a target price of $9. The...

In a report published Monday, H.C. Wainwright & Co. analyst Reni Benjamin initiated coverage on Agenus (NASDAQ: AGEN) with a Buy rating and $8.00 price target. In the report, H.C. Wainwright & Co. noted, “We are initiating coverage of Agenus with a BUY rating and a target price of $8. In...

In a report published Tuesday, H.C. Wainwright & Co. analyst George B. Zavoico initiated coverage on Prana Biotechnology (NASDAQ: PRAN) with a Buy rating and $20.50 price target. In the report, H.C. Wainwright & Co. noted, “We are initiating coverage of Prana Biotechnology Ltd. with a BUY...

In a report published Friday, H.C. Wainwright & Co. analyst Caroline Stewart initiated a Neutral rating on Clovis Oncology (NASDAQ: CLVS) and set a price target of $55.00. In the report, H.C. Wainwright & Co. says "We believe that the current market valuation for CLVS fairly values: 1) CO-...

In a report published Monday, H.C. Wainwright & Co. analyst Reni Benjamin initiated coverage on Spectrum Pharmaceuticals (NASDAQ: SPPI) with a Buy rating and $15.00 price target. In the report, H.C. Wainwright & Co. noted, “We are initiating coverage of Spectrum Pharmaceuticals with a BUY...